Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours

Wei Ouyang; Ran Xu; Hanyu Yao; Shusuan Jiang; Qiang Lu; Cai Lv; Pei Li; Genming Xu; Jianye Liu; Long Wang

doi:10.1002/ctm2.1549

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1549 DOI: 10.1002/ctm2.1549

LETTER TO THE JOURNAL

Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours

Author information +

History +

PDF

Cite this article

Download citation ▾

Wei Ouyang, Ran Xu, Hanyu Yao, Shusuan Jiang, Qiang Lu, Cai Lv, Pei Li, Genming Xu, Jianye Liu, Long Wang. Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours. Clinical and Translational Medicine, 2024, 14(1): e1549 DOI:10.1002/ctm2.1549

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int. 2004;72:99-102.

[2]	Ouyang W, Luo L, Zhang J, et al. Urine cellular DNA point mutation and methylation for identifying upper tract urinary carcinoma. Cancers (Basel). 2022;14:3537.

[3]	Zhang J, Xu R, Lu Q, Xu Z, Liu J, Li P, et al. A novel methylation marker NRN1 plus TERT and FGFR3 mutation using urine sediment enables the detection of urothelial bladder carcinoma. Cancers (Basel). 2023; 15:615.

[4]	Ou Z, Li K, Yang T, et al. Detection of bladder cancer using urinary cell-free DNA and cellular DNA. Clin Transl Med. 2020;9:4.

[5]	Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl. 2010;92:519-524.

[6]	Bishr M, Lattouf JB, Latour M, Saad F. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J. 2014;8:E306-310.

[7]	Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108-112.

[8]	Wang P, Shi Y, Zhang J, et al. UCseek: ultrasensitive early detection and recurrence monitoring of urothelial carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment DNA. EBioMedicine. 2023;89:104437.

[9]	Springer SU, Chen CH, Rodriguez Pena MDC, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife. 2018;7:e32143.

[10]	Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130:6278-6289.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.